Antigen-Presenting Cell Applications for Targeted Lysosomal Cell Death
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases such as Nonalcoholic Steatohepatitis (NASH), neurodegenerative diseases like Alzheimer's and Parkinson's, obesity, pulmonary fibrosis, congestive heart failure, and cancer are multifactorial and lack effective methods to target and remove specific cell types contributing to these conditions.
Innovation Solution
The use of a composition comprising an enzyme and an antibody that targets lysosomes of senescent cells, fat cells, fibroblasts, or cancer cells, inducing immunogenic cell death through increased lysosomal membrane permeability and reactive oxygen species production, leading to targeted cell removal.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current multifactorial treatments are used for diseases such as NASH, neurodegenerative diseases, obesity, pulmonary fibrosis, congestive heart failure, and cancer, then general disease management is achieved, but effective targeted removal of specific cell types contributing to these conditions is not possible
Solution Approach 1:
The treatment approach segments the complex disease problem into specific target cells (senescent cells, fat cells, fibroblasts, or cancer cells) and uses targeted compositions to address each cell type individually, rather than treating the disease as a monolithic entity
Solution Approach 2:
The patent employs fusion proteins as intermediary molecules that combine antibody components (for target recognition) with enzyme components (for lysosomal membrane permeabilization), enabling precise delivery of the killing mechanism to the target cell
2Reliability
If targeted cell removal is achieved through immunogenic cell death, then disease progression is retarded or reversed, but the mechanism requires complex fusion proteins combining antibodies and enzymes
Solution Approach 1:
The patent merges the antibody component (responsible for target cell recognition and binding) with the enzyme component (responsible for lysosomal membrane permeabilization and cell death) into a single fusion protein molecule, combining multiple functions in one therapeutic agent
Solution Approach 2:
The fusion protein composition is designed to perform multiple functions simultaneously: target cell recognition, lysosomal membrane permeabilization, and induction of immunogenic cell death, making a single molecule multi-functional rather than requiring separate agents
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces the quantity of target cells, thereby retarding or reversing the progression of the associated diseases by triggering an immune response and apoptosis, providing a targeted treatment mechanism.
Implementation Method 1
the enzyme is configured to increase lysosomal membrane permeability of the cell
Implementation Method 2
the enzyme is configured to create reactive oxygen species
Data Source
AI summary
The present disclosure generally relates to systems and methods for treating and/or reversing a disease or condition such as aging, nonalcoholic steatohepatitis (NASH), neurodegenerative disease such as Alzheimer's and Parkinson's, obesity pulmonary fibrosis, congestive heart failure, or cancer using immunogenic cell death, e.g., lysosome-induced immunogenic cell death. In certain embodiments, the application is directed towards compositions that comprise an antibody and an enzyme capable of producing reactive oxygen species. In some cases, the lysosome of cells associated with the disease or condition may be targeted by the composition for induced cell death.